TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23403945

Group type: EXPERIMENTAL
Intervention: Insulin infusion with 100 ml 5% dextrose/h
Number of subjects: 10

Group type: COMPARATOR
Intervention: Glucose infusion (100 ml/h)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Physiological saline (100 ml/h)
Number of subjects: 10
Study: 21054229

Group type: EXPERIMENTAL
Intervention: Simultaneous sinus mucosal lining elevation and placement of dental implants without graft materials
Number of subjects: 15

Group type: COMPARATOR
Intervention: Simultaneous sinus mucosal lining elevation and placement of dental implants with intraoral autogenous bone graft
Number of subjects: 15
Study: 20217948

Group type: EXPERIMENTAL
Intervention: Positive attitude towards medication
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Gender (Female)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Self-care orientation
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Medication knowledge
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Pharmacy visits
Number of subjects: 500
Study: 17124283

Group type: EXPERIMENTAL
Intervention: Risedronate 2.5 mg/day (group B)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Risedronate only (group C)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Active vitamin D only (group A)
Number of subjects: 114
Study: 15507930

Group type: EXPERIMENTAL
Intervention: Intravaginal metronidazole for 5 days
Number of subjects: 119

Group type: COMPARATOR
Intervention: Clindamycin for 3 days
Number of subjects: 119
Study: 11513817

Group type: EXPERIMENTAL
Intervention: 100-g amino acid (AA) drink devoid of tryptophan
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 9635910

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam 4 g i.v. Q6H
Number of subjects: 150

Group type: COMPARATOR
Intervention: Imipenem 500 mg i.v. Q6H
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam
Number of subjects: 150

Group type: COMPARATOR
Intervention: Imipenem
Number of subjects: 150
Study: 7828694

Group type: EXPERIMENTAL
Intervention: Turbuhaler
Number of subjects: 37

Group type: COMPARATOR
Intervention: P-MDI
Number of subjects: 37
Study: 3124598

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN) for 10 days
Number of subjects: 0
Study: 31609293

Group type: EXPERIMENTAL
Intervention: LBW protocol (679 mg iodine/kg for men, 762 mg iodine/kg for women)
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: LBW protocol (620.7 mg iodine/kg)
Number of subjects: 529

Group type: COMPARATOR
Intervention: Both LBW and TBW protocols
Number of subjects: 529
Study: 29151034

Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/40 mg
Number of subjects: 18144

Group type: COMPARATOR
Intervention: placebo/simvastatin 40 mg
Number of subjects: 18144
Study: 24882567

Group type: EXPERIMENTAL
Intervention: Psilocybin (.16 mg/kg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Psilocybin
Number of subjects: 25
Study: 23241007

Group type: EXPERIMENTAL
Intervention: Mandibular Protraction Appliance-IV (MPA-IV)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Twin-block appliance
Number of subjects: 83

Group type: COMPARATOR
Intervention: Class II controls
Number of subjects: 83
Study: 21524241

Group type: EXPERIMENTAL
Intervention: OrthoCAD iQ indirect bonding (IDB)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Traditional IDB technique
Number of subjects: 46
Study: 18559549

Group type: EXPERIMENTAL
Intervention: High intake of flavonols (4th quartile during the trial)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High intake of isoflavonoids, kaempferol, genistein, and formononetin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total flavonoid intake
Number of subjects: 0
Study: 16520578

Group type: EXPERIMENTAL
Intervention: ST35 & Sulan moxibustion
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no moxibustion)
Number of subjects: 34
Study: 14567819

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol 100 mug
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11126207

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg t.i.d. during the first year
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg t.i.d. during the second year
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo t.i.d. during the first year
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo t.i.d. during the second year
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Orlistat treatment
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 72
Study: 9097890

Group type: EXPERIMENTAL
Intervention: Diazepam 10mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clonidine 200 microg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8246033

Group type: EXPERIMENTAL
Intervention: Gallium nitrate treatment (30 mg/m2/d for 2 weeks, followed by 2 weeks off, plus 100 mg/m2/d IV for 5 days every other month)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gallium nitrate treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 20
Study: 3513669

Group type: EXPERIMENTAL
Intervention: Ketotifen 1 mg bid
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 29044496

Group type: COMPARATOR
Intervention: Carboplatin, paclitaxel, and bevacizumab (CPB)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Carboplatin, paclitaxel, bevacizumab, and everolimus (CPBE)
Number of subjects: 149
Study: 27794449

Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 118

Group type: COMPARATOR
Intervention: Stretching control
Number of subjects: 118
Study: 24252050

Group type: EXPERIMENTAL
Intervention: iguratimod + MTX
Number of subjects: 0

Group type: COMPARATOR
Intervention: (placebo/iguratimod) + MTX
Number of subjects: 0
Study: 23507369

Group type: EXPERIMENTAL
Intervention: 20 mg fluoxetine and high dose folic acid (5 mg/day; n=19; Group II)
Number of subjects: 42

Group type: COMPARATOR
Intervention: 20 mg fluoxetine and low dose folic acid (1.5 mg/day; n=23; Group I)
Number of subjects: 42
Study: 20797449

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU)
Number of subjects: 1106

Group type: COMPARATOR
Intervention: Not applicable (placebo-controlled)
Number of subjects: 1106
Study: 18405960

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Structured intervention
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 186
Study: 16027695

Group type: EXPERIMENTAL
Intervention: Massage therapy (moderate pressure)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham massage (light pressure)
Number of subjects: 0
Study: 14561017

Group type: EXPERIMENTAL
Intervention: Elderly apnoeics (EA)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Young apnoeics (YA)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Elderly non-apnoeics (EN)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Young non-apnoeics (YN)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Elderly apnoeics (EA) and Young apnoeics (YA)
Number of subjects: 44
Study: 11199194

Group type: EXPERIMENTAL
Intervention: Quantitative computed tomography (QCT)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry (DXA)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Comparison of QCT and DXA
Number of subjects: 64
Study: 8804010

Group type: EXPERIMENTAL
Intervention: Biocompatible membranes
Number of subjects: 2

Group type: COMPARATOR
Intervention: Cuprophane membranes
Number of subjects: 2
Study: 1629748

Group type: EXPERIMENTAL
Intervention: 160/800 mg b.i.d. orally x 3 days
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 160/800 mg i.m. x 10 days
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 160/800 mg b.i.d. orally x 20 days
Number of subjects: 75
Study: 6396117

Group type: EXPERIMENTAL
Intervention: Bifonazole solution (daily for 2 weeks)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Selenium sulphide shampoo (2.5% daily for 1 week and weekly for 6 weeks)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Bifonazole solution
Number of subjects: 38
Study: 31478763

Group type: EXPERIMENTAL
Intervention: 0/1-hour hs-cTnT protocol
Number of subjects: 3378
Study: 27941065

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg daily)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Evolocumab (420 mg every 2 weeks)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Combination of Atorvastatin and Evolocumab
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 81
Study: 25943660

Group type: EXPERIMENTAL
Intervention: Acetaminophen (ACT) 20 mg/kg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 9
Study: 25128046

Group type: EXPERIMENTAL
Intervention: Half-dose etanercept (25 mg/wk)
Number of subjects: 834

Group type: COMPARATOR
Intervention: Full-dose etanercept (50 mg/wk)
Number of subjects: 834

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 834
Study: 22561530

Group type: EXPERIMENTAL
Intervention: Real CPAP
Number of subjects: 65

Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 65
Study: 19955880

Group type: EXPERIMENTAL
Intervention: 90-minute in-service education program
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 129
Study: 17602075

Group type: EXPERIMENTAL
Intervention: Formal psychotherapeutic support during hospital stay
Number of subjects: 271

Group type: COMPARATOR
Intervention: Standard care as provided on the surgical wards
Number of subjects: 271
Study: 15841578

Group type: EXPERIMENTAL
Intervention: CeraOne abutments (Nobel Biocare AB)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Procera ceramic abutments (Nobel Biocare AB)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 18
Study: 16115972

Group type: EXPERIMENTAL
Intervention: Acupressure at the Yintang point
Number of subjects: 61

Group type: COMPARATOR
Intervention: Sham acupressure
Number of subjects: 61

Group type: COMPARATOR
Intervention: Acupressure and Sham
Number of subjects: 61
Study: 10341165

Group type: COMPARATOR
Intervention: D‐tagatose
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Lactitol
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 50
Study: 8583588

Group type: EXPERIMENTAL
Intervention: High water intake (group 1)
Number of subjects: 199

Group type: COMPARATOR
Intervention: No treatment (group 2)
Number of subjects: 199
Study: 1759956

Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy with exposure and response prevention (CBT + ERP)
Number of subjects: 0
Study: 7047984

Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg p.o.)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (100 mg p.o.)
Number of subjects: 6
Study: 30892782

Group type: EXPERIMENTAL
Intervention: Propofol and ketamine (KP group)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Propofol monosedation (Pm group)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 81
Study: 30071784

Group type: EXPERIMENTAL
Intervention: Advance care planning (ACP) event
Number of subjects: 188
Study: 26853953

Group type: EXPERIMENTAL
Intervention: Prompt revascularization (PR) with intensive medical therapy (IMT)
Number of subjects: 2368

Group type: COMPARATOR
Intervention: Intensive medical therapy (IMT) alone
Number of subjects: 2368

Group type: COMPARATOR
Intervention: Non-CTO group
Number of subjects: 2368
Study: 24045979

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (600 μg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravenous oxytocin (10 IU)
Number of subjects: 100
Study: 20977608

Group type: EXPERIMENTAL
Intervention: Partial overdentures supported with single immediately loaded implant in symphyseal region
Number of subjects: 12

Group type: COMPARATOR
Intervention: Removable metallic partial denture
Number of subjects: 12
Study: 20919774

Group type: EXPERIMENTAL
Intervention: Ingroup faces
Number of subjects: 0

Group type: COMPARATOR
Intervention: Outgroup faces
Number of subjects: 0
Study: 17141741

Group type: EXPERIMENTAL
Intervention: Cholinergic medication (acetylcholinesterase inhibitor)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: REM sleep augmentation (physiological rebound)
Number of subjects: 107

Group type: COMPARATOR
Intervention: REM sleep deprivation (via REM sleep awakenings)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Non-REM sleep awakenings
Number of subjects: 107
Study: 15860521

Group type: EXPERIMENTAL
Intervention: Perindopril 8 mg once daily
Number of subjects: 1502

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1502
Study: 12221896

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray, 200 mcg once daily
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo vehicle
Number of subjects: 206
Study: 10461471

Group type: EXPERIMENTAL
Intervention: Intra-articular hyaluronic acid (HA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 7828381

Group type: EXPERIMENTAL
Intervention: 20 mg S‐nitrendipine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 20 mg racemic nitrendipine
Number of subjects: 6

Group type: COMPARATOR
Intervention: 20 mg R‐nitrendipine
Number of subjects: 6

Group type: COMPARATOR
Intervention: 80 mg R‐nitrendipine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 26101836

Group type: EXPERIMENTAL
Intervention: High-frequency TENS (HF-TENS)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Low-frequency TENS (LF-TENS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo TENS (P-TENS)
Number of subjects: 15
Study: 23519225

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 21463065

Group type: EXPERIMENTAL
Intervention: Oxycodone 10 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oxycodone 20 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 17398308

Group type: EXPERIMENTAL
Intervention: EPA (eicosapentaenoic acid) 1800 mg daily with statin
Number of subjects: 18645

Group type: COMPARATOR
Intervention: Statin only (control)
Number of subjects: 18645

Group type: EXPERIMENTAL
Intervention: EPA treatment in patients with a history of coronary artery disease
Number of subjects: 18645

Group type: EXPERIMENTAL
Intervention: EPA treatment in patients with no history of coronary artery disease
Number of subjects: 18645
Study: 16146489

Group type: EXPERIMENTAL
Intervention: 400 mg/day topiramate
Number of subjects: 470

Group type: COMPARATOR
Intervention: 50 mg/day topiramate
Number of subjects: 470
Study: 12270591

Group type: EXPERIMENTAL
Intervention: Stimuli presented with low probability of occurrence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Application of abstract rules in categorization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No rules applied in categorization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulus probability effect in Experiment 2
Number of subjects: 0
Study: 10363865

Group type: EXPERIMENTAL
Intervention: Subcutaneous ardeparin 50 anti-Xa U/kg (low dose)
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Subcutaneous ardeparin 100 anti-Xa U/kg (high dose)
Number of subjects: 565

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: All treatment groups (including ardeparin and placebo)
Number of subjects: 565
Study: 8559491

Group type: EXPERIMENTAL
Intervention: High-flux SPAN membrane
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High-flux polysulphone (F60)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Low-flux Hemophan (GFS Plus 16)
Number of subjects: 9
Study: 2043015

Group type: EXPERIMENTAL
Intervention: Home glucose monitoring
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Fructosamine
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Total glycated hemoglobin
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Hemoglobin A1c
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Random serum glucose
Number of subjects: 17
Study: 6183631

Group type: EXPERIMENTAL
Intervention: Elimination of foodstuffs in a double-blind trial
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rechallenge with foods that caused histamine release
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dietary manipulation (open-trial basis)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ingestion of certain foodstuffs correlated to oral ulceration
Number of subjects: 60
Study: 31112379

Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg, administered orally twice daily
Number of subjects: 576

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 576
Study: 29860524

Group type: EXPERIMENTAL
Intervention: brief cognitive behavioral therapy (bCBT)
Number of subjects: 175

Group type: COMPARATOR
Intervention: enhanced usual care (EUC)
Number of subjects: 175
Study: 26945186

Group type: EXPERIMENTAL
Intervention: 1000 μg anisodamine
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 2000 μg anisodamine
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 4000 μg anisodamine
Number of subjects: 140

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 140
Study: 24595578

Group type: EXPERIMENTAL
Intervention: Ivermectin 1% cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study: 21943940

Group type: EXPERIMENTAL
Intervention: iopromide
Number of subjects: 475

Group type: COMPARATOR
Intervention: iodixanol
Number of subjects: 475
Study: 18498362

Group type: EXPERIMENTAL
Intervention: Two-implant overdenture (IOD)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional denture (CD)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups (CD and IOD)
Number of subjects: 36
Study: 17665604

Group type: EXPERIMENTAL
Intervention: Fenspiride (anti-inflammatory drug)
Number of subjects: 24
Study: 15588160

Group type: EXPERIMENTAL
Intervention: Orlistat plus exercise-induced weight loss (OEWL)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Orlistat-induced weight loss (OWL)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Exercise-induced weight loss (EWL)
Number of subjects: 24
Study: 12090577

Group type: EXPERIMENTAL
Intervention: Absorbable sutures (2-0 Dexon II)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Nonabsorbable sutures (2-0 Prolene)
Number of subjects: 162
Study: 10460526

Group type: EXPERIMENTAL
Intervention: Target-controlled propofol
Number of subjects: 61

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 61
Study: 7598067

Group type: EXPERIMENTAL
Intervention: Calcium supplement (increased average calcium intake by 17.9 mmol/d or 714 mg/d)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (unsupplemented)
Number of subjects: 60
Study: 2221586

Group type: EXPERIMENTAL
Intervention: Naloxone (0.1 mg/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 6
Study: 29347

Group type: EXPERIMENTAL
Intervention: Sodium citrate preparation (Citro‐Soda; Abbott) 4 g single dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium citrate preparation (Citro‐Soda; Abbott) 12 g single dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium citrate preparation (Citro‐Soda; Abbott) 4 g and 12 g doses after 3-6 days of continuous therapy every 6 hours
Number of subjects: 0
Study: 30826255

Group type: EXPERIMENTAL
Intervention: Keeping the Body in Mind Xtend pilot lifestyle program
Number of subjects: 0
Study: 29381788

Group type: EXPERIMENTAL
Intervention: Sleep extension group (n = 21) received a behavioral consultation session targeting sleep hygiene
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Sleep extension group (n = 21)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (n = 21)
Number of subjects: 42
Study: 27447966

Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC = 5, day 2) plus Paclitaxel (175 mg/m2, day 1)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Epirubicin (75 mg/m2, day 1) plus Paclitaxel (175 mg/m2, day 2)
Number of subjects: 91
Study: 23703878

Group type: COMPARATOR
Intervention: Surgical cutdown (C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Percutaneous access (P)
Number of subjects: 30
Study: 23296282

Group type: EXPERIMENTAL
Intervention: Hypo-energetic diet (-600 kcal/day)
Number of subjects: 771

Group type: COMPARATOR
Intervention: High-fat diet
Number of subjects: 771
Study: 21121410

Group type: EXPERIMENTAL
Intervention: salbutamol 2 mg + bromhexine HCI 8 mg + guaiphenesin 100 mg (group A)
Number of subjects: 426

Group type: COMPARATOR
Intervention: salbutamol 2 mg + guaiphenesin 100 mg (group B)
Number of subjects: 426

Group type: COMPARATOR
Intervention: salbutamol 2 mg + bromhexine 8 mg (group C)
Number of subjects: 426
Study: 17951945

Group type: EXPERIMENTAL
Intervention: Omega-3 (2 gm pearls per day, given in two equal doses)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (no Omega-3 supplementation)
Number of subjects: 33
Study: 16208150

Group type: EXPERIMENTAL
Intervention: Perindopril/indapamide
Number of subjects: 556

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 556
Study: 12118962

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin-piperacillin
Number of subjects: 471

Group type: COMPARATOR
Intervention: Tobramycin-piperacillin
Number of subjects: 471
Study: 10396473

Group type: EXPERIMENTAL
Intervention: Planned outpatient follow up 6‐12 weeks after surgery
Number of subjects: 264

Group type: COMPARATOR
Intervention: No planned follow up
Number of subjects: 264
Study: 7594073

Group type: EXPERIMENTAL
Intervention: Radionuclide angiography
Number of subjects: 73

Group type: COMPARATOR
Intervention: X-ray angiography
Number of subjects: 73
Study: 2273081

Group type: EXPERIMENTAL
Intervention: Moxonidine (0.25 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 7247286

Group type: EXPERIMENTAL
Intervention: Radical mastectomy
Number of subjects: 534

Group type: COMPARATOR
Intervention: Modified radical mastectomy
Number of subjects: 534